Bioconjugate Cleanup TFF: ADC Purification Without Chromatography

Q: What is the minimum sample volume the µPulse® TFF system can process for bioconjugate cleanup?

The µPulse® is designed specifically for research-scale applications and can process starting volumes as low as 500 µL of crude reaction mixture. Its industry-leading low hold-up volume means up to 100% of your sample is recovered — a critical advantage when working with high-value ADC or oligonucleotide conjugates where every microliter counts.

By Muhammad Sajed — Senior Application Scientist, Formulatrix

Bioconjugation has revolutionized modern medicine. From antibody-drug conjugates (ADCs) that deliver cytotoxic payloads directly to tumors, to oligonucleotide complexes and fluorescently labeled proteins, these engineered molecules combine biological specificity with functional chemistry. But between a successful conjugation reaction and a viable product lies a critical challenge: cleanup and formulation.

For a deeper look at how teams are standardizing this workflow, visit our Bioconjugate Cleanup application page.

The Cleanup Challenge

After conjugation, your reaction vessel contains far more than your target product. It is crowded with unreacted small-molecule drugs, excess linkers, solvents, and buffer components. Left unchecked, these impurities destabilize the conjugate, trigger aggregation, and compromise its functionality.

Bioconjugates are inherently delicate. Therefore, the cleanup stage must prioritize integrity as much as speed. The ADCs, for example, must maintain both the structural integrity of the antibody and the chemical stability of its cytotoxic payload. One of the key quality attributes for ADCs is the drug-to-antibody ratio (DAR), which directly influences efficacy and safety¹. Any purification method must preserve the DAR achieved during conjugation. High shear forces, prolonged processing, or harsh conditions during cleanup can lead to payload detachment (disruption of DARs), denaturation, or aggregation, irreversibly compromising the ADC's functionality.

The Conventional Workflow: A Fragmented Multistep Process

Walk into any research lab performing bioconjugation, and you'll likely witness a familiar, labor-intensive sequence.

Step 1: Purification

After the reaction, the researcher typically turns to purification, mostly using column chromatography. Size exclusion chromatography (SEC) is widely used² but it requires multiple column equilibration and wash steps. The sample is loaded, fractions are collected, and the purified conjugate emerges after careful elution. While this addresses purity, the resulting product is often dilute and trapped in an intermediate buffer.

Step 2: Formulation

The purified fractions must be concentrated and exchanged into a final storage buffer, typically using dead-end filtration (DEF). DEF-based spin columns are a popular lab‑scale choice: you load the sample, centrifuge, discard the flow‑through, add fresh buffer, and repeat. The sample is forced directly against the membrane, blocking the pores and risking aggregation. The only way to track the sample volume is by periodic interruption of centrifugation.

Dead-End Filtration

This fragmented approach requires multiple hand-offs, manual volume checks “by eye,” and repeated handling, creating multiple opportunities for sample loss, and extended hands-on time.

The Single-Step Solution: Tangential Flow Filtration

Tangential flow filtration (TFF) offers a fundamentally different approach that combines purification and formulation into a single,
integrated workflow.

Here's how it works:

In TFF, the sample flows parallel to the membrane surface rather than directly into it. Transmembrane pressure drives small molecules through the membrane pores and into the filtrate. Meanwhile, the larger bioconjugate is retained and continuously recirculated.

But here's the critical difference: Purification and formulation are no longer discrete steps. While the small-molecule impurities are being washed away, the system simultaneously introduces the final buffer into the closed loop. This means that both purification and formulation are performed within a single, continuous process - diafiltration.

Tangential-Flow Filtration

You start with a crude reaction mixture and end with a purified, concentrated, formulation-ready conjugate, without any manual buffer exchanges or sample transfers.

Why Does This Matter for Your Workflow?

This single-step approach transforms the laboratory experience as the one that is:

Continuous: Instead of discrete steps with pauses, the process runs uninterrupted from start to finish.

Gentle: The tangential flow sweeps the membrane surface continuously, preventing the fouling and concentration polarization that plague DEF. Shear stress is minimized—critical for maintaining delicate conjugate structures.

Efficient: Impurities are flushed away while your conjugate remains safely in circulation. The integrated concentration means you achieve your target volume without separate steps.

Reproducible: With automated control, the process follows the same parameters every time. No variation from manual volume checks or inconsistent handling.

Benchtop Automation: From Industrial Processes to Lab Scale

For years, this integrated workflow was limited to industrial scales because the systems were too large and complex, and required sample volumes far beyond the capacity of a research laboratory.

Formulatrix^® has changed this by miniaturizing TFF into the µPulse^® and its high-throughput counterpart, the aµtoPulse^®, to deliver the single-step workflow directly to your bench:

Maximize Sample Recovery

Start with as little as 500 µL of crude reaction mixture. The industry's lowest hold-up volume, which is up to 100 % recoverable using built-in options, ensures that your valuable sample isn't lost in the system's dead space. In a head-to-head study, the µPulse delivered a final ADC yield comparable to the SEC+DEF approach, while preserving critical quality attributes like DAR and monomer purity³.

Automate Concentration Control

Program your target concentration factor and buffer exchange extent. The system handles the rest, monitoring the run in real-time using weight-based sensing. This eliminates the guesswork of "checking volumes by eye" and ensures consistent results regardless of the operator.

True "Walk-Away" Efficiency:

There are no manual interventions required. A scientist can simply load the crude mixture, set the parameters, and return to a finished product that is purified, concentrated, and in its final formulation buffer.

From Complex Mixture to Finished Conjugate: One Workflow

Whether you're working with antibody-drug conjugates, oligonucleotide-protein complexes, or fluorescent labels, the workflow is the same:

Choose an appropriate molecular weight cutoff
Load your crude reaction mixture
Set your target parameters
Start the run
Collect your purified, formulated conjugate

No chromatography columns. No centrifugal filters. No multiple hand-offs: just a single, automated process from start to finish.

Conclusion

Pilot run bioconjugate cleanup no longer requires a fragmented, multistep workflow that introduces inefficiency, risk, and variability at every transition.

Automated lab-scale TFF replaces this with a singular solution: one process, one system, one seamless workflow from crude mixture to finished product. Higher purity, better yields, and reproducible results, without compromising the integrity of your delicate conjugates.

References

1. Casavant, J., Ratnayake, A. S., Puthenveetil, S., & Tumey, L. N. (2020). Detection and removal of small molecule and endotoxin contaminants in ADC preparations. Methods in Molecular Biology, 2078, 291–299.
https://doi.org/10.1007/978-1-4939-9929-3_20

2. Matsuda, Y. (2022). Current approaches for the purification of antibody–drug conjugates. Journal of Separation Science, 45, 27–37.
https://doi.org/10.1002/jssc.202100575

3. Sajed, M., Khan, Z., Ashraf, M. U., Iftikhar, H., Rahat, T. B., Falak, S., Fozail, S., Gue, Q., Pardo, R., Ramsey, L., & Shahzad, M. S. (2025). Single-step purification and formulation of antibody-drug conjugates using a miniaturized tangential flow filtration system. SLAS Technology, 35, 100351.
https://doi.org/10.1016/j.slast.2025.100351

Ready to transform your bioconjugate workflow?

Discover how the µPulse and the aµtoPulse TFF systems streamline your lab-scale workflows, automating purification and formulation in a single step.

Learn More About the µPulse

Learn More About the aµtoPulse

FAQs

What is the minimum sample volume the µPulse - TFF system can process for bioconjugate cleanup?

The µPulse is designed specifically for research-scale applications and can process starting volumes as low as 500 µL of crude reaction mixture. Its industry-leading low hold-up volume means up to 100% of your sample is recovered, a critical advantage when working with high-value ADC or oligonucleotide conjugates where every microliter counts.

Can TFF replace both purification and buffer exchange in a single bioconjugate cleanup run?

Yes. Unlike conventional workflows that treat size-based purification and buffer exchange as separate steps, often requiring column chromatography followed by dead-end centrifugal filtration, the µPulse and aµtoPulse perform both simultaneously in one closed-loop process. Small-molecule impurities (unreacted drugs, excess linkers, solvents) are continuously washed away while the final formulation buffer is introduced in real time. You start with a crude reaction mixture and end with a purified, concentrated, formulation-ready conjugate without any manual transfers.

How does TFF protect sensitive bioconjugates like ADCs from degradation during cleanup?

Dead-end filtration forces your sample directly against a membrane under centrifugal pressure, generating concentration polarization and shear stress that can denature antibodies, detach cytotoxic payloads, or cause aggregation. TFF avoids this by flowing the sample tangentially across the membrane surface, which continuously sweeps away accumulating solutes and minimizes transmembrane pressure. The result is a gentler process that preserves both the structural integrity of the antibody and the chemical stability of the payload throughout cleanup.

What is the difference between the µPulse and the aµtoPulse for bioconjugate workflows?

Both systems perform the same single-step purification and formulation workflow using tangential flow filtration, but they differ in throughput. The µPulse is a benchtop system optimized for individual research runs at small scale, ideal for method development, pilot cleanup, or low-volume precious samples. The aµtoPulse is its high-throughput counterpart, designed for labs running parallel bioconjugate cleanup campaigns where multiple samples need to be processed consistently and simultaneously without operator-to-operator variability.

How does the µPulse ensure reproducible results across bioconjugate cleanup runs?

Reproducibility failures in conventional cleanup typically stem from manual steps: volume checks done "by eye," inconsistent centrifugation times, and variable buffer replenishment. The µPulse eliminates these failure points through automated, weight-based real-time monitoring. You program your target concentration factor and diafiltration extent; the system executes the run to those exact parameters every time. No operator judgment is required between start and finish, making it straightforward to transfer methods between team members or scale across instruments.